Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

ABSTRACT:

Importance

Combined treatment with dabrafenib and trametinib (CombiDT) achieves clinical responses in only about 15% of patients with BRAF inhibitor (BRAFi)-refractory metastatic melanoma in contrast to the higher response rate observed in BRAFi-naïve patients. Identifying correlates of response and mechanisms of resistance in this population will facilitate clinical management and rational therapeutic development.

Objective

To determine correlates of benefit from CombiDT therapy in patients with BRAFi-refractory metastatic melanoma.

Design, setting, and participants

Single-center, single-arm, open-label phase 2 trial of CombiDT treatment in patients with BRAF V600 metastatic melanoma resistant to BRAFi monotherapy conducted between September 2012 and October 2014 at

SUBMITTER: Chen G 

PROVIDER: S-EPMC4982774 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature